$LUMO
Lumos Pharma Inc Stock $lumo

$lumo Overview Financials Valuation SEC Filings Company Website

2017 Q4 Form 10-Q Financial Statement

#000112623417000107 Filed on November 03, 2017

Income Statement

Concept	2017 Q4	2017 Q3	2016 Q3
Revenue	$10.10M	$5.482M	$15.35M
YoY Change	-20.51%	-64.28%	7.99%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.600M	$7.900M	$7.700M
YoY Change	-22.22%	2.6%	4.05%
% of Gross Profit
Research & Development	$16.90M	$18.48M	$24.46M
YoY Change	-16.34%	-24.46%	8.69%
% of Gross Profit
Depreciation & Amortization	$300.0K	$400.0K	$300.0K
YoY Change	-50.0%	33.33%	-40.0%
% of Gross Profit
Operating Expenses	$22.40M	$26.39M	$32.21M
YoY Change	-18.25%	-18.08%	7.76%
Operating Profit	-$14.05M	-$20.91M	-$16.69M
YoY Change	0.58%	25.28%	6.4%
Interest Expense	$300.0K	$3.000K	$5.000K
YoY Change	200.0%	-40.0%	-94.32%
% of Operating Profit
Other Income/Expense, Net	$0.00	$160.0K	$19.00K
YoY Change	-100.0%	742.11%	-130.16%
Pretax Income	-$13.80M	-$20.75M	-$16.85M
YoY Change	0.0%	23.13%	7.0%
Income Tax	-$100.0K	-$119.0K	-$1.308M
% Of Pretax Income
Net Earnings	-$13.69M	-$20.63M	-$15.54M
YoY Change	1.33%	32.73%	-2.3%
Net Earnings / Revenue	-135.53%	-376.25%	-101.27%
Basic Earnings Per Share	-$0.37	-$0.69	-$0.54
Diluted Earnings Per Share	-$3.341M	-$6.242M	-$0.54
COMMON SHARES
Basic Shares Outstanding	37.08M shares	29.42M shares	28.98M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q4	2017 Q3	2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$158.7M	$120.7M	$148.3M
YoY Change	20.68%	-18.61%	-26.0%
Cash & Equivalents	$158.7M	$120.7M	$148.3M
Short-Term Investments			$0.00
Other Short-Term Assets	$6.200M	$2.700M	$10.70M
YoY Change	5.08%	-74.77%	494.44%
Inventory
Prepaid Expenses			$10.69M
Receivables
Other Receivables	$10.18M	$10.67M
Total Short-Term Assets	$175.5M	$134.2M	$179.2M
YoY Change	4.5%	-25.1%	-17.51%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.091M	$5.527M	$7.188M
YoY Change	-25.52%	-23.11%	-25.34%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$5.231M	$5.527M	$7.188M
YoY Change	-23.47%	-23.11%	-25.34%
TOTAL ASSETS
Total Short-Term Assets	$175.5M	$134.2M	$179.2M
Total Long-Term Assets	$5.231M	$5.527M	$7.188M
Total Assets	$180.7M	$139.7M	$186.3M
YoY Change	3.4%	-25.02%	-17.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.256M	$11.86M	$2.367M
YoY Change	-59.55%	401.06%	58.43%
Accrued Expenses	$12.47M	$13.83M	$37.26M
YoY Change	-12.87%	-62.88%	356.89%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$200.0K	$200.0K	$200.0K
YoY Change	0.0%	0.0%	-64.16%
Total Short-Term Liabilities	$22.03M	$26.09M	$40.65M
YoY Change	-41.88%	-35.81%	262.42%
LONG-TERM LIABILITIES
Long-Term Debt	$100.0K	$100.0K	$300.0K
YoY Change	-66.67%	-66.67%	-26.65%
Other Long-Term Liabilities	$7.000M	$7.000M	$7.100M
YoY Change	-1.41%	-1.41%	-8.97%
Total Long-Term Liabilities	$7.109M	$7.159M	$7.422M
YoY Change	-3.62%	-3.54%	-9.4%
TOTAL LIABILITIES
Total Short-Term Liabilities	$22.03M	$26.09M	$40.65M
Total Long-Term Liabilities	$7.109M	$7.159M	$7.422M
Total Liabilities	$29.14M	$33.25M	$48.07M
YoY Change	-35.65%	-30.83%	147.68%
SHAREHOLDERS EQUITY
Retained Earnings	-$237.5M	-$223.8M	-$152.0M
YoY Change	43.47%	47.22%	158.6%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$1.142M	$1.113M	$784.0K
YoY Change	33.88%	41.96%	42.29%
Treasury Stock Shares	58.57K shares	55.78K shares	25.23K shares
Shareholders Equity	$151.6M	$106.5M	$138.3M
YoY Change
Total Liabilities & Shareholders Equity	$180.7M	$139.7M	$186.3M
YoY Change	3.4%	-25.02%	-17.84%

Cashflow Statement

Concept	2017 Q4	2017 Q3	2016 Q3
OPERATING ACTIVITIES
Net Income	-$13.69M	-$20.63M	-$15.54M
YoY Change	1.33%	32.73%	-2.3%
Depreciation, Depletion And Amortization	$300.0K	$400.0K	$300.0K
YoY Change	-50.0%	33.33%	-40.0%
Cash From Operating Activities	-$17.20M	-$7.200M	-$13.20M
YoY Change	1.18%	-45.45%	88.57%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$100.0K	-$100.0K
YoY Change	-100.0%	-200.0%	-92.31%
Acquisitions
YoY Change
Other Investing Activities	$100.0K	$0.00	$0.00
YoY Change			-100.0%
Cash From Investing Activities	$100.0K	$0.00	-$100.0K
YoY Change	-150.0%	-100.0%	-66.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	55.20M	20.00M	1.100M
YoY Change	13700.0%	1718.18%	10.0%
NET CHANGE
Cash From Operating Activities	-17.20M	-7.200M	-13.20M
Cash From Investing Activities	100.0K	0.000	-100.0K
Cash From Financing Activities	55.20M	20.00M	1.100M
Net Change In Cash	38.10M	12.80M	-12.20M
YoY Change	-326.79%	-204.92%	93.65%
FREE CASH FLOW
Cash From Operating Activities	-$17.20M	-$7.200M	-$13.20M
Capital Expenditures	$0.00	$100.0K	-$100.0K
Free Cash Flow	-$17.20M	-$7.300M	-$13.10M
YoY Change	1.78%	-44.27%	129.82%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Registrant Name EntityRegistrantName	NEWLINK GENETICS CORP
	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-102000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	397000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	260000	USD
	us-gaap	Payments For Restructuring PaymentsForRestructuring	1085000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2069000	USD
CY2014	nlnk	Collaborative Arrangement Numberof Arrangements CollaborativeArrangementNumberofArrangements	2	arrangement
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Period End Date DocumentPeriodEndDate	2017-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001126234
CY2017Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	37077159	shares
CY2016Q4	nlnk	Deferred Government Grants Obligations Noncurrent DeferredGovernmentGrantsObligationsNoncurrent	6000000	USD
CY2017Q3	nlnk	Deferred Government Grants Obligations Noncurrent DeferredGovernmentGrantsObligationsNoncurrent	6000000	USD
CY2016Q4	nlnk	Government Contract Accrued Subcontractor Fees GovernmentContractAccruedSubcontractorFees	2900000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14309000	USD
CY2017Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13832000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5700000	USD
CY2017Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6700000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	295535000	USD
CY2017Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	331036000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14938000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13100000	USD
CY2017Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4400000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14900000	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	3976000	USD
CY2017Q3	us-gaap	Assets Assets	139714000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	167912000	USD
CY2017Q3	us-gaap	Assets Current AssetsCurrent	134187000	USD
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	231000	USD
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	195620000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	148276000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	131490000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	120702000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-47344000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-10788000	USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	561000	USD
CY2016Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3900000	USD
CY2017Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2016Q4	us-gaap	Assets Assets	174747000	USD
CY2017Q3	nlnk	Government Contract Accrued Subcontractor Fees GovernmentContractAccruedSubcontractorFees	1400000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	22883000	USD
CY2017Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	11860000	USD
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2017Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29193718	shares
CY2017Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31375528	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29163673	shares
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	391000	USD
CY2017Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	112000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1536000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1064000	USD
CY2017Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31319751	shares
CY2016Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	292000	USD
CY2017Q3	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	314000	USD
CY2016Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	90000	USD
CY2017Q3	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	93000	USD
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1091000	USD
CY2017Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1021000	USD
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.54
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.48
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7749000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	26043000	USD
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.69
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.98
	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	640000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	25038000	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7907000	USD
CY2016Q4	us-gaap	Government Contract Receivable GovernmentContractReceivable	23900000	USD
CY2017Q3	us-gaap	Government Contract Receivable GovernmentContractReceivable	10100000	USD
CY2016Q4	us-gaap	Government Contract Receivable Unbilled Amounts GovernmentContractReceivableUnbilledAmounts	4300000	USD
CY2017Q3	us-gaap	Government Contract Receivable Unbilled Amounts GovernmentContractReceivableUnbilledAmounts	1500000	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16848000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-76670000	USD
CY2017Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-20745000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-58694000	USD
CY2016Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1300000	USD
CY2016Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1308000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5021000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5000000	USD
CY2017Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-119000	USD
CY2017Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-119000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-429000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-429000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1022000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-6261000	USD
CY2016Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	5975000	USD
CY2017Q3	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	114000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	27204000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-11500000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-6056000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	5861000	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	79000	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	67000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-606000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-279000	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	9607000	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-13856000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5734000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3220000	USD
CY2016Q3	us-gaap	Interest Expense InterestExpense	5000	USD
	us-gaap	Interest Expense InterestExpense	18000	USD
CY2017Q3	us-gaap	Interest Expense InterestExpense	3000	USD
	us-gaap	Interest Expense InterestExpense	116000	USD
	us-gaap	Interest Paid InterestPaid	18000	USD
	us-gaap	Interest Paid InterestPaid	11000	USD
CY2016Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	68000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	180000	USD
CY2017Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	151000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	353000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	45281000	USD
CY2017Q3	us-gaap	Liabilities Liabilities	33250000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	174747000	USD
CY2017Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	139714000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	37905000	USD
CY2017Q3	us-gaap	Liabilities Current LiabilitiesCurrent	26091000	USD
CY2016Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	7376000	USD
CY2017Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	7159000	USD
CY2017Q3	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	843000	USD
CY2016Q3	us-gaap	Licenses Revenue LicensesRevenue	888000	USD
	us-gaap	Licenses Revenue LicensesRevenue	3008000	USD
CY2017Q3	us-gaap	Licenses Revenue LicensesRevenue	103000	USD
	us-gaap	Licenses Revenue LicensesRevenue	334000	USD
CY2016Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	285000	USD
CY2017Q3	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	138000	USD
CY2016Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	232000	USD
CY2017Q3	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	194000	USD
CY2016Q4	us-gaap	Long Term Debt And Capital Lease Obligations Including Current Maturities LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities	517000	USD
CY2017Q3	us-gaap	Long Term Debt And Capital Lease Obligations Including Current Maturities LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities	332000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1478000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20140000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	111000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	142000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-48933000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-31070000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-15540000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-71649000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-20626000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-58265000	USD
CY2016Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	19000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	118000	USD
CY2017Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	160000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	136000	USD
	us-gaap	Notes Reduction NotesReduction	397000	USD
	us-gaap	Notes Reduction NotesReduction	0	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	32212000	USD
	us-gaap	Operating Expenses OperatingExpenses	99853000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	26387000	USD
	us-gaap	Operating Expenses OperatingExpenses	77443000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-16867000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-76788000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-20905000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-58830000	USD
CY2016Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-44000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-44000	USD
CY2017Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	12000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-101000	USD
CY2016Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	24526000	USD
CY2017Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	10670000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	13000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	43000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2017Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2017Q3	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5921000	USD
CY2017Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2701000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1686000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	20585000	USD
	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities	2180000	USD
	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities	0	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	185000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6835000	USD
CY2017Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5527000	USD
	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	195000	USD
	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	185000	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24463000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	73810000	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18480000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	52405000	USD
CY2017Q3	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.50
CY2016	us-gaap	Restructuring Charges RestructuringCharges	12300000	USD
	us-gaap	Restructuring Charges RestructuringCharges	1695000	USD
CY2016Q4	us-gaap	Restructuring Reserve RestructuringReserve	42000	USD
CY2017Q3	us-gaap	Restructuring Reserve RestructuringReserve	652000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-165508000	USD
CY2017Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-223773000	USD
CY2016Q3	us-gaap	Revenue From Grants RevenueFromGrants	14457000	USD
	us-gaap	Revenue From Grants RevenueFromGrants	20057000	USD
CY2017Q3	us-gaap	Revenue From Grants RevenueFromGrants	5379000	USD
	us-gaap	Revenue From Grants RevenueFromGrants	18279000	USD
CY2016Q3	us-gaap	Sales Revenue Net SalesRevenueNet	15345000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	23065000	USD
CY2017Q3	us-gaap	Sales Revenue Net SalesRevenueNet	5482000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	18613000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	13119000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	14938000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	326000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	19334000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	925000	USD
CY2017Q3	us-gaap	Stockholders Equity StockholdersEquity	106464000	USD
	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	260000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	129466000	USD
CY2016	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	4000000	USD
CY2016Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	30045	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	29462226	shares
CY2017Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	55777	shares
CY2016Q4	us-gaap	Treasury Stock Value TreasuryStockValue	853000	USD
CY2017Q3	us-gaap	Treasury Stock Value TreasuryStockValue	1113000	USD
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	28983561	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	28911042	shares
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	29939823	shares
	us-gaap	Basis Of Accounting BasisOfAccounting	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements have been prepared and presented by the Company in accordance with U.S. generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the U.S. Securities and Exchange Commission (the SEC), and, in management’s opinion, reflect all adjustments necessary to present fairly the Company’s interim condensed financial information.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, included in the Company’s Annual Report on Form 10-K. There were no significant changes in the Company’s accounting policies since the end of fiscal </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. The financial results for any interim period are not necessarily indicative of financial results for the full year.</font></div></div>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents are held by financial institutions and are federally insured up to certain limits. At times, the Company’s cash and cash equivalents balance exceeds the federally insured limits. To limit the credit risk, the Company invests its excess cash primarily in high-quality securities such as certificates of deposit and money market funds.</font></div></div>
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">escription of Business</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 4, 1999, NewLink Genetics Corporation (NewLink) was incorporated as a Delaware corporation. NewLink was formed for the purpose of developing treatments for patients with cancer and other diseases. NewLink initiated operations in April 2000. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NewLink and its subsidiaries (the Company) are devoting substantially all of their efforts toward research and development. The Company has never earned revenue from commercial sales of its drugs. The Company incurred a net loss of </font><font style="font-family:inherit;font-size:10pt;">$20.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$58.3 million</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2017, the Company undertook an organizational realignment to refocus its clinical development efforts and align the Company's resources to focus on the Company's highest value opportunities. The Company's restructuring activities included a reduction of its workforce by approximately </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;">, which consisted primarily of clinical and research and development staff, as well as stopping additional research on the Zika virus. Refer to Note 9 for more information.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements as of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;"> have been prepared assuming the Company will continue as a going concern. The Company successfully raised net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$37.6 million</font><font style="font-family:inherit;font-size:10pt;"> from its IPO, completed a follow-on offering of its common stock raising net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$49.0 million</font><font style="font-family:inherit;font-size:10pt;">, and raised an additional </font><font style="font-family:inherit;font-size:10pt;">$58.7 million</font><font style="font-family:inherit;font-size:10pt;"> in net proceeds from an at the market (ATM) offering completed in 2015.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 29, 2016, the Company entered into a Sales Agreement with Cantor Fitzgerald & Co. (Cantor) under which the Company may sell up to </font><font style="font-family:inherit;font-size:10pt;">$40.0 million</font><font style="font-family:inherit;font-size:10pt;"> of its common stock in one or more placements at prevailing market prices in an ATM offering. The Company launched this ATM offering in June 2017. During the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">1,940,656</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock were sold under this ATM, with aggregate net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$19.3 million</font><font style="font-family:inherit;font-size:10pt;"> after commissions of </font><font style="font-family:inherit;font-size:10pt;">$398,000</font><font style="font-family:inherit;font-size:10pt;"> paid to Cantor as the placement agent, and other costs of </font><font style="font-family:inherit;font-size:10pt;">$163,000</font><font style="font-family:inherit;font-size:10pt;"> . </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subsequent to </font><font style="font-family:inherit;font-size:10pt;">September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company sold </font><font style="font-family:inherit;font-size:10pt;">5,750,000</font><font style="font-family:inherit;font-size:10pt;"> of its shares of common stock in a public offering for aggregate net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$55.2 million</font><font style="font-family:inherit;font-size:10pt;"> after underwriters' discounts, commissions and other expenses of </font><font style="font-family:inherit;font-size:10pt;">$3.7 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> license and collaboration agreements the Company entered into during 2014, the Company received a nonrefundable upfront cash payment of </font><font style="font-family:inherit;font-size:10pt;">$150.0 million</font><font style="font-family:inherit;font-size:10pt;"> from Genentech Inc., a member of the Roche Group, or Genentech, in 2014, and a nonrefundable upfront cash payment of </font><font style="font-family:inherit;font-size:10pt;">$30.0 million</font><font style="font-family:inherit;font-size:10pt;"> from Merck, Sharpe and Dohme Corp., or Merck, in 2014, as well as a milestone payment of </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> from Merck in February 2015. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's cash and cash equivalents after these agreements and the offerings are expected to be adequate to satisfy the Company's liquidity requirements into the second quarter of 2020. If available liquidity becomes insufficient to meet the Company’s operating obligations as they come due, the Company's plans include pursuing alternative funding arrangements and/or reducing expenditures as necessary to meet the Company’s cash requirements. However, there is no assurance that, if required, the Company will be able to raise additional capital or reduce discretionary spending to provide the required liquidity. Failure by the Company to successfully execute its plans or otherwise address its liquidity needs may have a material adverse effect on its business and financial position, and may materially affect the Company’s ability to continue as a going concern.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001126234-17-000107-index-headers.html	Edgar Link	pending
0001126234-17-000107-index.html	Edgar Link	pending
0001126234-17-000107.txt	Edgar Link	pending
0001126234-17-000107-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
newlinklogorgbwtaga01a01a09.jpg	Edgar Link	pending
nlnk-20170930.xml	Edgar Link	completed
nlnk-20170930.xsd	Edgar Link	pending
nlnk-20170930x10q.htm	Edgar Link	pending
nlnk-20170930xex311.htm	Edgar Link	pending
nlnk-20170930xex312.htm	Edgar Link	pending
nlnk-20170930xex321.htm	Edgar Link	pending
nlnk-20170930_cal.xml	Edgar Link	unprocessable
nlnk-20170930_def.xml	Edgar Link	unprocessable
nlnk-20170930_lab.xml	Edgar Link	unprocessable
nlnk-20170930_pre.xml	Edgar Link	unprocessable
nlnkidoclinicalprioritiesa01.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LUMO
Lumos Pharma Inc Stock $lumo

2017 Q4 Form 10-Q Financial Statement

#000112623417000107 Filed on November 03, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LUMO Lumos Pharma Inc Stock $lumo

2017 Q4 Form 10-Q Financial Statement

#000112623417000107 Filed on November 03, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LUMO
Lumos Pharma Inc Stock $lumo